IPP Bureau

Transmural Systems wins breakthrough FDA nod for coronary-saving TAVR device
Transmural Systems wins breakthrough FDA nod for coronary-saving TAVR device

By IPP Bureau - November 27, 2025

The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions

Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech
Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech

By IPP Bureau - November 27, 2025

The fresh capital will propel Cordance into its first-in-human clinical trial

Glenmark launches world’s first nebulized triple therapy for COPD
Glenmark launches world’s first nebulized triple therapy for COPD

By IPP Bureau - November 27, 2025

Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness

India’s pharma industry showcases innovation, global ambitions at CPHI & PMEC India 2025
India’s pharma industry showcases innovation, global ambitions at CPHI & PMEC India 2025

By IPP Bureau - November 27, 2025

India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem

Novo Nordisk fast-tracks higher-dose obesity drug to FDA
Novo Nordisk fast-tracks higher-dose obesity drug to FDA

By IPP Bureau - November 27, 2025

The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway

Lords Mark bets big on AI-driven dialysis tech, buys 85% stake in Renalyx Health
Lords Mark bets big on AI-driven dialysis tech, buys 85% stake in Renalyx Health

By IPP Bureau - November 27, 2025

Renalyx will continue operating as an independent unit within the group

Dr. Lal PathLabs launches India's first complement testing lab
Dr. Lal PathLabs launches India's first complement testing lab

By IPP Bureau - November 27, 2025

The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards

SMS Pharmaceutical's associate company receives FDA approval for reformulated Ranitidine
SMS Pharmaceutical's associate company receives FDA approval for reformulated Ranitidine

By IPP Bureau - November 27, 2025

The approval by the US FDA comes after extensive safety testing and manufacturing improvements

Zydus inks licensing, commercialisation pact with RK Pharma
Zydus inks licensing, commercialisation pact with RK Pharma

By IPP Bureau - November 27, 2025

RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US

FDA nod to AstraZeneca’s Imfinzi plus FLOT chemotherapy for early and locally advanced gastric cancer
FDA nod to AstraZeneca’s Imfinzi plus FLOT chemotherapy for early and locally advanced gastric cancer

By IPP Bureau - November 27, 2025

Dhoni joins Arth by Emcure to tackle iron deficiency on World Iron Deficiency Day
Dhoni joins Arth by Emcure to tackle iron deficiency on World Iron Deficiency Day

By IPP Bureau - November 27, 2025

FDA updates label for Sun Pharma’s UNLOXCYT, highlighting durable responses in advanced skin cancer
FDA updates label for Sun Pharma’s UNLOXCYT, highlighting durable responses in advanced skin cancer

By IPP Bureau - November 27, 2025

The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses

Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial

By IPP Bureau - November 27, 2025

Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors

Enlivex reports promising six-month data for Allocetra in knee osteoarthritis
Enlivex reports promising six-month data for Allocetra in knee osteoarthritis

By IPP Bureau - November 27, 2025

Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide

Cidara hits target enrollment for Phase 3 flu trial ahead of peak season
Cidara hits target enrollment for Phase 3 flu trial ahead of peak season

By IPP Bureau - November 27, 2025

CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents

Latest Stories

Interviews

Packaging